8 minute read
Apr. 2, 2024
RMC-6291: Reprogramming a Molecular Glue to Target KRAS
RMC-6291
oral KRASG12C(ON) tri-complex inhibitor Ph. I/II for adv. solid tumors from FBDD + SBDD AACR, October 2023 Revolution Medicines, Redwood City, CA
Loading...
oral KRASG12C(ON) tri-complex inhibitor Ph. I/II for adv. solid tumors from FBDD + SBDD AACR, October 2023 Revolution Medicines, Redwood City, CA